CNS 2024 is the annual conference hosted by the prestigious Cognitive Neuroscience Society (CNS). The upcoming event is scheduled to take place from September 28th to October 2nd in Houston, Texas. This year’s conference is anticipated to be particularly engaging, offering attendees the opportunity to explore cutting-edge advancements in neurosurgery and their impact on enhancing […]
Read More
On July 2, 2024, the US Food and Drug Administration (FDA) granted approval for Eli Lilly’s Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. This treatment is recommended for patients in the early stages of the disease, specifically those with mild cognitive impairment or mild dementia, as demonstrated in the clinical trials. Kisunla marks […]
Read MoreThe American Academy of Neurology (AAN) has announced that their latest guideline, “Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Update: Report of the AAN Guidelines Subcommittee,” is now open for public comment. This practice guideline offers updated evidence-based conclusions and recommendations on the use of pharmacologic migraine prevention in adults. The primary objective […]
Read More
Duchenne Muscular Dystrophy (DMD) is a severe inherited neuromuscular disorder caused by mutations in the dystrophin gene. It leads to progressive muscle wasting and irreversible functional decline. Primarily affecting males due to X-linked recessive inheritance, DMD can also rarely affect females. Symptoms include gradual muscle atrophy and fibrous tissue replacement in skeletal and cardiac muscles. […]
Read More